Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease

Saori Yaguchi, Yoko Ogawa, Shigeto Shimmura, Tetsuya Kawakita, Shin Hatou, Shingo Satofuka, Shigeru Nakamura, Toshihiro Imada, Hideyuki Miyashita, Satoru Yoshida, Tomonori Yaguchi, Yoko Ozawa, Takehiko Mori, Shinichiro Okamoto, Yutaka Kawakami, Susumu Ishida, Kazuo Tsubota

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic HSCT (hematopoietic stem cell transplantation), is characterized by systemic fibrosis. The tissue renin-angiotensin system (RAS) is involved in the fibrotic pathogenesis, and an angiotensin II type 1 receptor (AT1R) antagonist can attenuate fibrosis. Tissue RAS is present in the lacrimal gland, lung, and liver, and is known to be involved in the fibrotic pathogenesis of the lung and liver. This study aimed to determine whether RAS is involved in fibrotic pathogenesis in the lacrimal gland and to assess the effect of an AT1R antagonist on preventing lacrimal gland, lung, and liver fibrosis in cGVHD model mice. We used the B10.D2→BALB/c (H-2d) MHC-compatible, multiple minor histocompatibility antigen-mismatched model, which reflects clinical and pathological symptoms of human cGVHD. First, we examined the localization and expression of RAS components in the lacrimal glands using immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). Next, we administered an AT1R antagonist (valsartan; 10 mg/kg) or angiotensin II type 2 receptor (AT2R) antagonist (PD123319; 10 mg/kg) intraperitoneally into cGVHD model mice and assessed the fibrotic change in the lacrimal gland, lung, and liver. We demonstrated that fibroblasts expressed angiotensin II, AT1R, and AT2R, and that the mRNA expression of angiotensinogen was greater in the lacrimal glands of cGVHD model mice than in controls generated by syngeneic-HSCT. The inhibition experiment revealed that fibrosis of the lacrimal gland, lung, and liver was suppressed in mice treated with the AT1R antagonist, but not the AT2R antagonist. We conclude that RAS is involved in fibrotic pathogenesis in the lacrimal gland and that AT1R antagonist has a therapeutic effect on lacrimal gland, lung, and liver fibrosis in cGVHD model mice. Our findings point to AT1R antagonist as a possible target for therapeutic intervention in cGVHD.

Original languageEnglish
Article numbere64724
JournalPLoS One
Volume8
Issue number6
DOIs
Publication statusPublished - 2013 Jun 6

Fingerprint

lacrimal apparatus
Angiotensin II Type 1 Receptor Blockers
Lacrimal Apparatus
liver cirrhosis
angiotensin II
Graft vs Host Disease
Grafts
Liver Cirrhosis
Liver
antagonists
Angiotensins
animal models
lungs
Renin
Lung
receptors
renin-angiotensin system
Renin-Angiotensin System
Angiotensin II Type 2 Receptor Blockers
disease models

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease. / Yaguchi, Saori; Ogawa, Yoko; Shimmura, Shigeto; Kawakita, Tetsuya; Hatou, Shin; Satofuka, Shingo; Nakamura, Shigeru; Imada, Toshihiro; Miyashita, Hideyuki; Yoshida, Satoru; Yaguchi, Tomonori; Ozawa, Yoko; Mori, Takehiko; Okamoto, Shinichiro; Kawakami, Yutaka; Ishida, Susumu; Tsubota, Kazuo.

In: PLoS One, Vol. 8, No. 6, e64724, 06.06.2013.

Research output: Contribution to journalArticle

Yaguchi, Saori ; Ogawa, Yoko ; Shimmura, Shigeto ; Kawakita, Tetsuya ; Hatou, Shin ; Satofuka, Shingo ; Nakamura, Shigeru ; Imada, Toshihiro ; Miyashita, Hideyuki ; Yoshida, Satoru ; Yaguchi, Tomonori ; Ozawa, Yoko ; Mori, Takehiko ; Okamoto, Shinichiro ; Kawakami, Yutaka ; Ishida, Susumu ; Tsubota, Kazuo. / Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease. In: PLoS One. 2013 ; Vol. 8, No. 6.
@article{071b26a49e354a54a1c8c8085853433a,
title = "Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease",
abstract = "Chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic HSCT (hematopoietic stem cell transplantation), is characterized by systemic fibrosis. The tissue renin-angiotensin system (RAS) is involved in the fibrotic pathogenesis, and an angiotensin II type 1 receptor (AT1R) antagonist can attenuate fibrosis. Tissue RAS is present in the lacrimal gland, lung, and liver, and is known to be involved in the fibrotic pathogenesis of the lung and liver. This study aimed to determine whether RAS is involved in fibrotic pathogenesis in the lacrimal gland and to assess the effect of an AT1R antagonist on preventing lacrimal gland, lung, and liver fibrosis in cGVHD model mice. We used the B10.D2→BALB/c (H-2d) MHC-compatible, multiple minor histocompatibility antigen-mismatched model, which reflects clinical and pathological symptoms of human cGVHD. First, we examined the localization and expression of RAS components in the lacrimal glands using immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). Next, we administered an AT1R antagonist (valsartan; 10 mg/kg) or angiotensin II type 2 receptor (AT2R) antagonist (PD123319; 10 mg/kg) intraperitoneally into cGVHD model mice and assessed the fibrotic change in the lacrimal gland, lung, and liver. We demonstrated that fibroblasts expressed angiotensin II, AT1R, and AT2R, and that the mRNA expression of angiotensinogen was greater in the lacrimal glands of cGVHD model mice than in controls generated by syngeneic-HSCT. The inhibition experiment revealed that fibrosis of the lacrimal gland, lung, and liver was suppressed in mice treated with the AT1R antagonist, but not the AT2R antagonist. We conclude that RAS is involved in fibrotic pathogenesis in the lacrimal gland and that AT1R antagonist has a therapeutic effect on lacrimal gland, lung, and liver fibrosis in cGVHD model mice. Our findings point to AT1R antagonist as a possible target for therapeutic intervention in cGVHD.",
author = "Saori Yaguchi and Yoko Ogawa and Shigeto Shimmura and Tetsuya Kawakita and Shin Hatou and Shingo Satofuka and Shigeru Nakamura and Toshihiro Imada and Hideyuki Miyashita and Satoru Yoshida and Tomonori Yaguchi and Yoko Ozawa and Takehiko Mori and Shinichiro Okamoto and Yutaka Kawakami and Susumu Ishida and Kazuo Tsubota",
year = "2013",
month = "6",
day = "6",
doi = "10.1371/journal.pone.0064724",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Angiotensin II Type 1 Receptor Antagonist Attenuates Lacrimal Gland, Lung, and Liver Fibrosis in a Murine Model of Chronic Graft-Versus-Host Disease

AU - Yaguchi, Saori

AU - Ogawa, Yoko

AU - Shimmura, Shigeto

AU - Kawakita, Tetsuya

AU - Hatou, Shin

AU - Satofuka, Shingo

AU - Nakamura, Shigeru

AU - Imada, Toshihiro

AU - Miyashita, Hideyuki

AU - Yoshida, Satoru

AU - Yaguchi, Tomonori

AU - Ozawa, Yoko

AU - Mori, Takehiko

AU - Okamoto, Shinichiro

AU - Kawakami, Yutaka

AU - Ishida, Susumu

AU - Tsubota, Kazuo

PY - 2013/6/6

Y1 - 2013/6/6

N2 - Chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic HSCT (hematopoietic stem cell transplantation), is characterized by systemic fibrosis. The tissue renin-angiotensin system (RAS) is involved in the fibrotic pathogenesis, and an angiotensin II type 1 receptor (AT1R) antagonist can attenuate fibrosis. Tissue RAS is present in the lacrimal gland, lung, and liver, and is known to be involved in the fibrotic pathogenesis of the lung and liver. This study aimed to determine whether RAS is involved in fibrotic pathogenesis in the lacrimal gland and to assess the effect of an AT1R antagonist on preventing lacrimal gland, lung, and liver fibrosis in cGVHD model mice. We used the B10.D2→BALB/c (H-2d) MHC-compatible, multiple minor histocompatibility antigen-mismatched model, which reflects clinical and pathological symptoms of human cGVHD. First, we examined the localization and expression of RAS components in the lacrimal glands using immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). Next, we administered an AT1R antagonist (valsartan; 10 mg/kg) or angiotensin II type 2 receptor (AT2R) antagonist (PD123319; 10 mg/kg) intraperitoneally into cGVHD model mice and assessed the fibrotic change in the lacrimal gland, lung, and liver. We demonstrated that fibroblasts expressed angiotensin II, AT1R, and AT2R, and that the mRNA expression of angiotensinogen was greater in the lacrimal glands of cGVHD model mice than in controls generated by syngeneic-HSCT. The inhibition experiment revealed that fibrosis of the lacrimal gland, lung, and liver was suppressed in mice treated with the AT1R antagonist, but not the AT2R antagonist. We conclude that RAS is involved in fibrotic pathogenesis in the lacrimal gland and that AT1R antagonist has a therapeutic effect on lacrimal gland, lung, and liver fibrosis in cGVHD model mice. Our findings point to AT1R antagonist as a possible target for therapeutic intervention in cGVHD.

AB - Chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic HSCT (hematopoietic stem cell transplantation), is characterized by systemic fibrosis. The tissue renin-angiotensin system (RAS) is involved in the fibrotic pathogenesis, and an angiotensin II type 1 receptor (AT1R) antagonist can attenuate fibrosis. Tissue RAS is present in the lacrimal gland, lung, and liver, and is known to be involved in the fibrotic pathogenesis of the lung and liver. This study aimed to determine whether RAS is involved in fibrotic pathogenesis in the lacrimal gland and to assess the effect of an AT1R antagonist on preventing lacrimal gland, lung, and liver fibrosis in cGVHD model mice. We used the B10.D2→BALB/c (H-2d) MHC-compatible, multiple minor histocompatibility antigen-mismatched model, which reflects clinical and pathological symptoms of human cGVHD. First, we examined the localization and expression of RAS components in the lacrimal glands using immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). Next, we administered an AT1R antagonist (valsartan; 10 mg/kg) or angiotensin II type 2 receptor (AT2R) antagonist (PD123319; 10 mg/kg) intraperitoneally into cGVHD model mice and assessed the fibrotic change in the lacrimal gland, lung, and liver. We demonstrated that fibroblasts expressed angiotensin II, AT1R, and AT2R, and that the mRNA expression of angiotensinogen was greater in the lacrimal glands of cGVHD model mice than in controls generated by syngeneic-HSCT. The inhibition experiment revealed that fibrosis of the lacrimal gland, lung, and liver was suppressed in mice treated with the AT1R antagonist, but not the AT2R antagonist. We conclude that RAS is involved in fibrotic pathogenesis in the lacrimal gland and that AT1R antagonist has a therapeutic effect on lacrimal gland, lung, and liver fibrosis in cGVHD model mice. Our findings point to AT1R antagonist as a possible target for therapeutic intervention in cGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84878795830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878795830&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0064724

DO - 10.1371/journal.pone.0064724

M3 - Article

C2 - 23762250

AN - SCOPUS:84878795830

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e64724

ER -